

WO 2005/072770

10/587184

PCT/US2005/001139

1/26 AP20 Rec'd PCT/PTO 25 JUL 2006

SEQUENCE LISTING

<110> FERRING B.V.

<120> NOVEL USE

<130> 052209-0113

<150> US 60/538,512

<151> 2004-01-26

<160> 43

<170> PatentIn version 3.2

<210> 1

<211> 34

<212> PRT

<213> Homo sapiens

<400> 1

Ser	Val	Ser	Glu	Ile	Gln	Leu	Met	His	Asn	Leu	Gly	Lys	His	Leu	Asn
1				5					10					15	

Ser	Met	Glu	Arg	Val	Glu	Trp	Leu	Arg	Lys	Lys	Leu	Gln	Asp	Val	His
			20					25						30	

Asn Phe

<210> 2

<211> 34

<212> PRT

<213> Bos taurus

<400> 2

Ala	Val	Ser	Glu	Ile	Gln	Phe	Met	His	Asn	Leu	Gly	Lys	His	Leu	Ser
1				5					10					15	

Ser	Met	Glu	Arg	Val	Glu	Trp	Leu	Arg	Lys	Lys	Leu	Gln	Asp	Val	His
			20					25						30	

Asn Phe

<210> 3

<211> 34

<212> PRT

<213> Homo sapiens

WO 2005/072770

PCT/US2005/001139

2/26

<400> 3

Ala Val Ser Glu His Gln Leu Leu His Asp Lys Gly Lys Ser Ile Gln
1 5 10 15

Asp Leu Arg Arg Arg Phe Phe Leu His His Leu Ile Ala Glu Ile His
20 25 30

Thr Ala

<210> 4

<211> 34

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide

<220>

<221> MOD_RES

<222> (8)..(8)

<223> Nle

<220>

<221> MOD_RES

<222> (12)..(12)

<223> Aib

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Nle

<220>

<221> MOD_RES

<222> (23)..(23)

<223> 2-Nal

<220>

<223> see specification as filed for preferred embodiments

<400> 4

Ala Val Ser Glu Ile Gln Phe Xaa His Asn Leu Xaa Lys His Leu Ser
1 5 10 15

Ser Xaa Glu Arg Val Glu Xaa Leu Arg Lys Lys Leu Gln Asp Val His
20 25 30

Asn Tyr

WO 2005/072770

PCT/US2005/001139

3/26

<210> 5
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<223> see specification as filed for preferred embodiments

<400> 5
Ser Val Ser Glu Ile Gln Leu Met His Asn Leu Gly Lys His Leu Asn
1 5 10 15

Ser Met Glu Arg Val Glu Leu Leu Glu Lys Leu Leu Glu Lys Leu His
20 25 30

Asn Phe

<210> 6
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<223> see specification as filed for preferred embodiments

<400> 6
Ser Val Ser Glu Ile Gln Leu Met His Asn Leu Gly Lys His Leu Asn
1 5 10 15

Ser Met Glu Arg Val Glu Trp Leu Glu Lys Lys Leu Glu Lys Val His
20 25 30

Asn Phe

<210> 7
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

WO 2005/072770

PCT/US2005/001139

4/26

<220>

<223> see specification as filed for preferred embodiments

<400> 7

Ser	Val	Ser	Glu	Ile	Gln	Leu	Met	His	Asn	Leu	Gly	Lys	His	Leu	Asn
1				5					10					15	

Ser	Met	Glu	Arg	Val	Glu	Leu	Leu	Arg	Lys	Leu	Leu	Gln	Asp	Leu	His
		20						25					30		

Asn Phe

<210> 8

<211> 34

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide

<220>

<221> MOD_RES

<222> (26)..(26)

<223> Aib

<220>

<223> see specification as filed for preferred embodiments

<400> 8

Ala	Val	Ser	Glu	His	Gln	Leu	Leu	His	Asp	Lys	Gly	Lys	Ser	Ile	Gln
1				5					10					15	

Asp	Leu	Arg	Arg	Arg	Phe	Phe	Leu	His	Xaa	Leu	Ile	Ala	Glu	Ile	His
			20					25					30		

Thr Ala

<210> 9

<211> 34

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide

<220>

<221> MOD_RES

WO 2005/072770

PCT/US2005/001139

5/26

<222> (32)..(32)

<223> Thi

<220>

<223> see specification as filed for preferred embodiments

<400> 9

Ala	Val	Ser	Glu	His	Gln	Leu	Leu	His	Asp	Lys	Gly	Lys	Ser	Ile	Gln
1				5					10					15	

Asp	Leu	Arg	Arg	Arg	Glu	Leu	Leu	Glu	Lys	Leu	Leu	Glu	Lys	Leu	Xaa
		20						25					30		

Thr Ala

<210> 10

<211> 34

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide

<220>

<223> see specification as filed for preferred embodiments

<400> 10

Ala	Val	Ser	Glu	His	Gln	Leu	Leu	His	Asp	Lys	Gly	Lys	Ser	Ile	Gln
1				5					10					15	

Asp	Leu	Arg	Arg	Arg	Glu	Leu	Leu	Glu	Lys	Leu	Leu	Glu	Leu	Leu	His
		20						25					30		

Thr Ala

<210> 11

<211> 34

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide

<220>

<223> see specification as filed for preferred embodiments

<400> 11

Ala	Val	Ser	Glu	His	Gln	Leu	Leu	His	Asp	Lys	Gly	Lys	Ser	Ile	Gln
1				5					10					15	

WO 2005/072770

PCT/US2005/001139

6/26

Asp Leu Arg Arg Arg Phe Leu Leu His His Leu Leu Ala Glu Leu His
20 25 30

Thr Ala

<210> 12
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<223> see specification as filed for preferred embodiments

<400> 12
Ala Val Ser Glu His Gln Leu Leu His Asp Lys Gly Lys Ser Ile Gln
1 5 10 15

Asp Leu Arg Arg Arg Glu Phe Leu Glu Lys Leu Ile Glu Lys Ile His
20 25 30

Thr Ala

<210> 13
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> MOD_RES
<222> (8)..(8)
<223> Nle

<220>
<221> MOD_RES
<222> (18)..(18)
<223> beta-Ala

<220>
<221> MOD_RES
<222> (23)..(23)
<223> Nal

WO 2005/072770

PCT/US2005/001139

7/26

<220>

<223> see specification as filed for preferred embodiments

<400> 13

Ala Val Ser Glu Ile Gln Phe Xaa His Asn Leu Gly Lys His Leu Ser
1 5 10 15

Ser Xaa Glu Arg Val Glu Xaa Leu Arg Lys Lys Leu Gln Asp Val His
20 25 30

Asn Tyr

<210> 14

<211> 34

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide

<220>

<221> MOD_RES

<222> (8)..(8)

<223> Nle

<220>

<221> MOD_RES

<222> (18)..(19)

<223> beta-Ala

<220>

<221> MOD_RES

<222> (23)..(23)

<223> Nal

<220>

<223> see specification as filed for preferred embodiments

<400> 14

Ala Val Ser Glu Ile Gln Phe Xaa His Asn Leu Gly Lys His Leu Ser
1 5 10 15

Ser Xaa Xaa Arg Val Glu Xaa Leu Arg Lys Lys Leu Gln Asp Val His
20 25 30

Asn Tyr

WO 2005/072770

PCT/US2005/001139

8/26

<210> 15
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> MOD_RES
<222> (8)..(8)
<223> Nle

<220>
<221> MOD_RES
<222> (18)..(18)
<223> Nle

<220>
<221> MOD_RES
<222> (19)..(19)
<223> beta-Ala

<220>
<221> MOD_RES
<222> (23)..(23)
<223> Nal

<220>
<223> see specification as filed for preferred embodiments

<400> 15
Ala Val Ser Glu Ile Gln Phe Xaa His Asn Leu Gly Lys His Leu Ser
1 5 10 15

Ser Xaa Xaa Arg Val Glu Xaa Leu Arg Lys Lys Leu Gln Asp Val His
20 25 30

Asn Tyr

<210> 16
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> MOD_RES

WO 2005/072770

PCT/US2005/001139

9/26

<222> (8)..(8)

<223> Nle

<220>

<221> MOD_RES

<222> (18)..(18)

<223> beta-hLeu

<220>

<221> MOD_RES

<222> (19)..(19)

<223> beta-Ala

<220>

<221> MOD_RES

<222> (23)..(23)

<223> Nal

<220>

<223> see specification as filed for preferred embodiments

<400> 16

Ala	Val	Ser	Glu	Ile	Gln	Phe	Xaa	His	Asn	Leu	Gly	Lys	His	Leu	Ser
1				5					10					15	

Ser	Xaa	Xaa	Arg	Val	Glu	Xaa	Leu	Arg	Lys	Lys	Leu	Gln	Asp	Val	His
			20					25					30		

Asn Tyr

<210> 17

<211> 34

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide

<220>

<221> MOD_RES

<222> (8)..(8)

<223> Nle

<220>

<221> MOD_RES

<222> (17)..(17)

<223> beta-Ala

<220>

<221> MOD_RES

<222> (18)..(18)

<223> beta-hLeu

WO 2005/072770

PCT/US2005/001139

10/26

<220>

<221> MOD_RES

<222> (19)..(19)

<223> beta-Ala

<220>

<221> MOD_RES

<222> (23)..(23)

<223> Nal

<220>

<223> see specification as filed for preferred embodiments

<400> 17

Ala Val Ser Glu Ile Gln Phe Xaa His Asn Leu Gly Lys His Leu Ser
1 5 10 15

Xaa Xaa Xaa Arg Val Glu Xaa Leu Arg Lys Lys Leu Gln Asp Val His
20 25 30

Asn Tyr

<210> 18

<211> 34

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide

<220>

<221> MOD_RES

<222> (16)..(16)

<223> beta-Ala

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Nle

<220>

<223> see specification as filed for preferred embodiments

<400> 18

Ala Val Ser Glu Ile Gln Phe Met His Asn Leu Gly Lys His Leu Xaa
1 5 10 15

Ser Xaa Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His
20 25 30

WO 2005/072770

PCT/US2005/001139

11/26

Asn Phe

<210> 19
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> MOD_RES
<222> (18)..(18)
<223> Nle

<220>
<221> MOD_RES
<222> (20)..(20)
<223> beta-Ala

<220>
<223> see specification as filed for preferred embodiments

<400> 19
Ala Val Ser Glu Ile Gln Phe Met His Asn Leu Gly Lys His Leu Ser
1 5 10 15

Ser Xaa Glu Xaa Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His
 20 25 30

Asn Phe

<210> 20
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> MOD_RES
<222> (17)..(17)
<223> beta-Ala

<220>
<221> MOD_RES

WO 2005/072770

PCT/US2005/001139

12/26

<222> (18) .. (18)

<223> Nle

<220>

<223> see specification as filed for preferred embodiments

<400> 20

Ala	Val	Ser	Glu	Ile	Gln	Phe	Met	His	Asn	Leu	Gly	Lys	His	Leu	Ser
1				5					10					15	

Xaa	Xaa	Glu	Arg	Val	Glu	Trp	Leu	Arg	Lys	Lys	Leu	Gln	Asp	Val	His
			20					25					30		

Asn Phe

<210> 21

<211> 34

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide

<220>

<221> MOD_RES

<222> (18) .. (18)

<223> beta-Ala

<220>

<223> see specification as filed for preferred embodiments

<400> 21

Ala	Val	Ser	Glu	Ile	Gln	Phe	Met	His	Asn	Leu	Gly	Lys	His	Leu	Ser
1				5					10					15	

Ser	Xaa	Glu	Arg	Val	Glu	Trp	Leu	Arg	Lys	Lys	Leu	Gln	Asp	Val	His
			20					25					30		

Asn Phe

<210> 22

<211> 34

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide

WO 2005/072770

PCT/US2005/001139

13/26

<220>
<221> MOD_RES
<222> (18)..(18)
<223> Nle

<220>
<221> MOD_RES
<222> (19)..(19)
<223> beta-Ala

<220>
<223> see specification as filed for preferred embodiments

<400> 22
Ala Val Ser Glu Ile Gln Phe Met His Asn Leu Gly Lys His Leu Ser
1 5 10 15

Ser Xaa Xaa Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His
20 25 30

Asn Phe

<210> 23
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> MOD_RES
<222> (17)..(17)
<223> beta-hSer

<220>
<221> MOD_RES
<222> (18)..(18)
<223> Nle

<220>
<223> see specification as filed for preferred embodiments

<400> 23
Ala Val Ser Glu Ile Gln Phe Met His Asn Leu Gly Lys His Leu Ser
1 5 10 15

Xaa Xaa Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His
20 25 30

WO 2005/072770

PCT/US2005/001139

14/26

Asn Phe

<210> 24
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> MOD_RES
<222> (18)..(18)
<223> beta-hLeu

<220>
<223> see specification as filed for preferred embodiments

<400> 24
Ala Val Ser Glu Ile Gln Phe Met His Asn Leu Gly Lys His Leu Ser
1 5 10 15

Ser Xaa Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His
20 25 30

Asn Phe

<210> 25
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> MOD_RES
<222> (18)..(18)
<223> Nle

<220>
<221> MOD_RES
<222> (19)..(19)
<223> beta-hGlu

<220>
<223> see specification as filed for preferred embodiments

WO 2005/072770

PCT/US2005/001139

15/26

<400> 25

Ala Val Ser Glu Ile Gln Phe Met His Asn Leu Gly Lys His Leu Ser
1 5 10 15

Ser Xaa Xaa Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His
20 25 30

Asn Phe

<210> 26

<211> 34

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide

<220>

<221> MOD_RES

<222> (17)..(17)

<223> beta-Ala

<220>

<221> MOD_RES

<222> (18)..(18)

<223> beta-Ala

<220>

<223> see specification as filed for preferred embodiments

<400> 26

Ala Val Ser Glu Ile Gln Phe Met His Asn Leu Gly Lys His Leu Ser
1 5 10 15

Xaa Xaa Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His
20 25 30

Asn Phe

<210> 27

<211> 34

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide

WO 2005/072770

PCT/US2005/001139

16/26

<220>
<221> MOD_RES
<222> (18)..(19)
<223> beta-Ala

<220>
<223> see specification as filed for preferred embodiments

<400> 27
Ala Val Ser Glu Ile Gln Phe Met His Asn Leu Gly Lys His Leu Ser
1 5 10 15

Ser Xaa Xaa Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His
20 25 30

Asn Phe

<210> 28
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> MOD_RES
<222> (17)..(17)
<223> beta-Ala

<220>
<221> MOD_RES
<222> (18)..(18)
<223> Nle

<220>
<221> MOD_RES
<222> (19)..(19)
<223> beta-Ala

<220>
<223> see specification as filed for preferred embodiments

<400> 28
Ala Val Ser Glu Ile Gln Phe Met His Asn Leu Gly Lys His Leu Ser
1 5 10 15

Xaa Xaa Xaa Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His
20 25 30

WO 2005/072770

PCT/US2005/001139

17/26

Asn Phe

<210> 29
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> MOD_RES
<222> (17)..(17)
<223> beta-Ala

<220>
<221> MOD_RES
<222> (18)..(18)
<223> beta-hLeu

<220>
<223> see specification as filed for preferred embodiments

<400> 29
Ala Val Ser Glu Ile Gln Phe Met His Asn Leu Gly Lys His Leu Ser
1 5 10 15

Xaa Xaa Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His
20 25 30

Asn Phe

<210> 30
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> MOD_RES
<222> (18)..(18)
<223> beta-hLeu

<220>
<221> MOD_RES
<222> (19)..(19)
<223> beta-Ala

WO 2005/072770

PCT/US2005/001139

18/26

<220>

<223> see specification as filed for preferred embodiments

<400> 30

Ala Val Ser Glu Ile Gln Phe Met His Asn Leu Gly Lys His Leu Ser
1 5 10 15

Ser Xaa Xaa Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His
20 25 30

Asn Phe

<210> 31

<211> 34

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide

<220>

<221> MOD_RES

<222> (18)..(18)

<223> beta-Ala

<220>

<221> MOD_RES

<222> (19)..(19)

<223> beta-hGlu

<220>

<223> see specification as filed for preferred embodiments

<400> 31

Ala Val Ser Glu Ile Gln Phe Met His Asn Leu Gly Lys His Leu Ser
1 5 10 15

Ser Xaa Xaa Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His
20 25 30

Asn Phe

<210> 32

<211> 34

<212> PRT

<213> Artificial Sequence

WO 2005/072770

PCT/US2005/001139

19/26

<220>

<223> Synthetic peptide

<220>

<221> MOD_RES

<222> (17)..(17)

<223> beta-Ala

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Nle

<220>

<221> MOD_RES

<222> (19)..(19)

<223> beta-hGlu

<220>

<223> see specification as filed for preferred embodiments

<400> 32

Ala	Val	Ser	Glu	Ile	Gln	Phe	Met	His	Asn	Leu	Gly	Lys	His	Leu	Ser
1				5					10					15	

Xaa	Xaa	Xaa	Arg	Val	Glu	Trp	Leu	Arg	Lys	Lys	Leu	Gln	Asp	Val	His
			20				25					30			

Asn Phe

<210> 33

<211> 34

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide

<220>

<221> MOD_RES

<222> (17)..(17)

<223> beta-hSer

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Nle

<220>

<221> MOD_RES

WO 2005/072770

PCT/US2005/001139

20/26

<222> (19)..(19)

<223> beta-Ala

<220>

<223> see specification as filed for preferred embodiments

<400> 33

Ala	Val	Ser	Glu	Ile	Gln	Phe	Met	His	Asn	Leu	Gly	Lys	His	Leu	Ser
1				5					10					15	

Xaa	Xaa	Xaa	Arg	Val	Glu	Trp	Leu	Arg	Lys	Lys	Leu	Gln	Asp	Val	His
			20				25						30		

Asn Phe

<210> 34

<211> 35

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide

<220>

<221> MOD_RES

<222> (17)..(17)

<223> beta-hSer

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Nle

<220>

<221> MOD_RES

<222> (19)..(19)

<223> beta-Ala

<220>

<223> see specification as filed for preferred embodiments

<400> 34

Ala	Val	Ser	Glu	Ile	Gln	Phe	Met	His	Asn	Leu	Gly	Lys	His	Leu	Ser
1				5					10					15	

Xaa	Xaa	Xaa	Glu	Arg	Val	Glu	Trp	Leu	Arg	Lys	Lys	Leu	Gln	Asp	Val
			20				25						30		

His	Asn	Phe
		35

WO 2005/072770

PCT/US2005/001139

21/26

<210> 35
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> MOD_RES
<222> (17)..(17)
<223> beta-hSer

<220>
<221> MOD_RES
<222> (18)..(18)
<223> beta-Ala

<220>
<221> MOD_RES
<222> (19)..(19)
<223> beta-Ala

<220>
<223> see specification as filed for preferred embodiments

<400> 35
Ala Val Ser Glu Ile Gln Phe Met His Asn Leu Gly Lys His Leu Ser
1 5 10 15

Xaa Xaa Xaa Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His
20 25 30

Asn Phe

<210> 36
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> MOD_RES
<222> (17)..(18)
<223> beta-Ala

WO 2005/072770

PCT/US2005/001139

22/26

<220>

<221> MOD_RES

<222> (19)..(19)

<223> beta-hGlu

<220>

<223> see specification as filed for preferred embodiments

<400> 36

Ala Val Ser Glu Ile Gln Phe Met His Asn Leu Gly Lys His Leu Ser
1 5 10 15

Xaa Xaa Xaa Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His
20 25 30

Asn Phe

<210> 37

<211> 34

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide

<220>

<221> MOD_RES

<222> (17)..(17)

<223> beta-Ala

<220>

<221> MOD_RES

<222> (18)..(18)

<223> beta-hLeu

<220>

<221> MOD_RES

<222> (19)..(19)

<223> beta-Ala

<220>

<223> see specification as filed for preferred embodiments

<400> 37

Ala Val Ser Glu Ile Gln Phe Met His Asn Leu Gly Lys His Leu Ser
1 5 10 15

Xaa Xaa Xaa Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His
20 25 30

WO 2005/072770

PCT/US2005/001139

23/26

Asn Phe

<210> 38

<211> 34

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide

<220>

<221> MOD_RES

<222> (17)..(17)

<223> beta-hSer

<220>

<221> MOD_RES

<222> (18)..(18)

<223> beta-hLeu

<220>

<223> see specification as filed for preferred embodiments

<400> 38

Ala	Val	Ser	Glu	Ile	Gln	Phe	Met	His	Asn	Leu	Gly	Lys	His	Leu	Ser
1				5					10					15	

Xaa	Xaa	Glu	Arg	Val	Glu	Trp	Leu	Arg	Lys	Lys	Leu	Gln	Asp	Val	His
			20					25					30		

Asn Phe

<210> 39

<211> 34

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide

<220>

<221> MOD_RES

<222> (18)..(18)

<223> beta-hLeu

<220>

<221> MOD_RES

<222> (19)..(19)

<223> beta-hGlu

WO 2005/072770

PCT/US2005/001139

24/26

<220>

<223> see specification as filed for preferred embodiments

<400> 39

Ala	Val	Ser	Glu	Ile	Gln	Phe	Met	His	Asn	Leu	Gly	Lys	His	Leu	Ser
1				5					10					15	

Ser	Xaa	Xaa	Arg	Val	Glu	Trp	Leu	Arg	Lys	Lys	Leu	Gln	Asp	Val	His
			20					25					30		

Asn Phe

<210> 40

<211> 34

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide

<220>

<221> MOD_RES

<222> (17)..(17)

<223> beta-hSer

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Nle

<220>

<221> MOD_RES

<222> (19)..(19)

<223> beta-hGlu

<220>

<223> see specification as filed for preferred embodiments

<400> 40

Ala	Val	Ser	Glu	Ile	Gln	Phe	Met	His	Asn	Leu	Gly	Lys	His	Leu	Ser
1				5					10					15	

Xaa	Xaa	Xaa	Arg	Val	Glu	Trp	Leu	Arg	Lys	Lys	Leu	Gln	Asp	Val	His
			20					25					30		

Asn Phe

WO 2005/072770

PCT/US2005/001139

25/26

<210> 41
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> MOD_RES
<222> (17)..(17)
<223> beta-hSer

<220>
<221> MOD_RES
<222> (18)..(18)
<223> beta-hLeu

<220>
<221> MOD_RES
<222> (19)..(19)
<223> beta-hGlu

<220>
<223> see specification as filed for preferred embodiments

<400> 41
Ala Val Ser Glu Ile Gln Phe Met His Asn Leu Gly Lys His Leu Ser
1 5 10 15

Xaa Xaa Xaa Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His
20 25 30

Asn Phe

<210> 42
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> MOD_RES
<222> (8)..(8)
<223> Nle

<220>
<221> MOD_RES

WO 2005/072770

PCT/US2005/001139

26/26

<222> (12) .. (12)

<223> Aib

<220>

<221> MOD_RES

<222> (18) .. (18)

<223> Nle

<220>

<221> MOD_RES

<222> (23) .. (23)

<223> 2-Nal

<220>

<223> see specification as filed for preferred embodiments

<400> 42

Ser	Val	Ser	Glu	Ile	Gln	Leu	Xaa	His	Asn	Leu	Xaa	Lys	His	Leu	Asn
1				5					10					15	

Ser	Xaa	Glu	Arg	Val	Glu	Xaa	Leu	Arg	Lys	Lys	Leu	Gln	Asp	Val	His
			20					25					30		

Asn Tyr

<210> 43

<211> 34

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide

<220>

<221> MOD_RES

<222> (12) .. (12)

<223> Aib

<220>

<223> see specification as filed for preferred embodiments

<400> 43

Ser	Val	Ser	Glu	Ile	Gln	Leu	Met	His	Asn	Leu	Xaa	Lys	His	Leu	Asn
1				5					10					15	

Ser	Met	Glu	Arg	Val	Glu	Trp	Leu	Arg	Lys	Lys	Leu	Gln	Asp	Val	His
			20					25					30		

Asn Phe